GDTC – cytomed therapeutics limited - ordinary shares (US:NASDAQ)
Stock Stats
News
CytoMed Therapeutics (GDTC) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
Form 6-K CytoMed Therapeutics For: Apr 14
Form 6-K CytoMed Therapeutics For: Mar 31
Form 20-F CytoMed Therapeutics For: Dec 31
Form 144 CytoMed Therapeutics Filed by: mDR Ltd
Form 6-K CytoMed Therapeutics For: Jan 28
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.